DNB Markets analyst Rune Dahl double upgraded Genmab to Buy from Sell with an unchanged price target of DKK 2,450. The firm says the company’s Q3 beat its forecast and consensus on revenue and operating profit. After a 33% share price decline year-to-date, the analyst sees a favorable risk/reward. The buy-side has adjusted for higher costs, de-risking Genmab’s 2024 guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab to Present at Jefferies London Healthcare Conference
- Major Shareholder Announcement
- Genmab Announces Financial Results for the First Nine Months of 2023
- Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
- Biotech Alert: Searches spiking for these stocks today